Literature DB >> 22345339

Liver transplantation for autoimmune hepatitis in Peru: outcomes and recurrence.

Martín Padilla1, Rosario Mayorga, Félix Carrasco, Tayana Bedregal, Fernando Bobadilla, Carlos Rondón, José Chaman.   

Abstract

BACKGROUND: Liver transplantation is the only therapy for end-stage liver disease. Cirrhosis secondary to autoimmune hepatitis (AIH) is an indication in 4-6% of adult transplants. AIMS: To describe the outcomes and recurrence of AIH in liver transplant patients.
MATERIAL AND METHODS: Twenty patients were retrospectively studied.
RESULTS: The female/male ratio was 3:1, the median age was 36.7 years (range, 16 to 39 years), and the median MELD score was 18.5. According to serological analysis, 19 patients were AIH type 1 and one patient was AIH type 2. AIH was associated with human leukocyte antigen (HLA) DR13+ and DR4+. The overall 5-year patient and graft survival rates were 94 and 85%, respectively. Three (15.7%) cases of recurrent AIH were diagnosed based on histological evidence. Clinical and histological features of acute and chronic rejection were present in four (20%) and three (16.6%) patients, respectively.
CONCLUSION: AIH frequently affected young women, was the most frequent indication for liver transplantation. Rejection and recurrence were commonly associated with AIH, but did not affect patient survival. No significant relationship between HLA-DR type and recurrence was found. Rapid progression to cirrhosis should be considered in severe recurrences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345339

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  3 in total

1.  Impact of pretransplant antinuclear antibody and antismooth muscle antibody titers on disease recurrence and graft survival following liver transplantation in autoimmune hepatitis patients.

Authors:  Nader Dbouk; Samir Parekh
Journal:  J Gastroenterol Hepatol       Date:  2013-03       Impact factor: 4.029

Review 2.  Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement.

Authors:  Luis Antonio Díaz; Gustavo Ayares; Jorge Arnold; Francisco Idalsoaga; Oscar Corsi; Marco Arrese; Juan Pablo Arab
Journal:  Curr Treat Options Gastroenterol       Date:  2022-06-16

Review 3.  Genetics and genomics in Peru: Clinical and research perspective.

Authors:  Heinner Guio; Julio A Poterico; Kelly S Levano; Mario Cornejo-Olivas; Pilar Mazzetti; Gioconda Manassero-Morales; Manuel F Ugarte-Gil; Eduardo Acevedo-Vásquez; Milagros Dueñas-Roque; Alejandro Piscoya; Ricardo Fujita; Cesar Sanchez; Sandro Casavilca-Zambrano; Luis Jaramillo-Valverde; Yasser Sullcahuaman-Allende; Juan M Iglesias-Pedraz; Hugo Abarca-Barriga
Journal:  Mol Genet Genomic Med       Date:  2018-11       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.